摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

azepin-3-one | 75967-10-1

中文名称
——
中文别名
——
英文名称
azepin-3-one
英文别名
Oxo 3h azepine
azepin-3-one化学式
CAS
75967-10-1
化学式
C6H5NO
mdl
——
分子量
107.112
InChiKey
QAYPFHIZJSDUSF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    213.4±23.0 °C(Predicted)
  • 密度:
    1.04±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    29.4
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    azepin-3-one二碳酸二叔丁酯2-硝基苯肼1,4-二氧六环 、 CF3CH2OH 、 氯仿 为溶剂, 以52%的产率得到tert-butyl 7-nitro-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate
    参考文献:
    名称:
    Substituted heterocycle fused gamma-carbolines
    摘要:
    本发明涉及通过给予由结构式(I)表示的化合物或其药学上可接受的盐形式来治疗成瘾行为和睡眠障碍的方法,其中R1、R5、R6a、R6b、R7、R8、R9、X、b、k、m和n以及虚线如本文所述。本发明治疗方法中使用的化合物是5-羟色胺激动剂和拮抗剂,对于控制或预防包括成瘾行为和睡眠障碍在内的中枢神经系统疾病是有用的。
    公开号:
    US20040220178A1
点击查看最新优质反应信息

文献信息

  • [EN] MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS<br/>[FR] DERIVES DE MALONAMIDE UTILISES COMME INHIBITEURS DE LA GAMMA-SECRETASE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2004069826A1
    公开(公告)日:2004-08-19
    The invention relates to malonamide derivatives of formula (IA) or (IB) and to pharmaceutically suitable acid addition salts thereof. The compounds are Ϝ-secretase inhibitors and the related compounds may be useful in the treatment of Alzheimer's disease.
    这项发明涉及公式(IA)或(IB)的马隆酰胺衍生物及其药用适宜的酸盐。这些化合物是Ϝ-分泌酶抑制剂,相关化合物可能在治疗阿尔茨海默病方面有用。
  • [EN] BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS<br/>[FR] DERIVES DE BENZAZEPINE UTILES COMME INHIBITEURS DE MAO-B
    申请人:HOFFMANN LA ROCHE
    公开号:WO2005039591A1
    公开(公告)日:2005-05-06
    The present invention relates to novel benzazepine derivatives of the following formula: (I) wherein R1, R2, R3, R4 and R5, X, X’, Y and Y’ are as defined in the description and claims, processes for their preparation, pharmaceutical compositions containing said derivatives and their use for the preparation of medicaments useful for the prevention and treatment of diseases in which selective inhibition of monoamine oxidase B activity plays a role or is implicated.
    本发明涉及以下结构的新型苯哌啶衍生物:(I),其中R1、R2、R3、R4和R5,X、X'、Y和Y'如描述和权利要求中所定义,以及它们的制备方法、含有所述衍生物的药物组合物,以及它们用于制备对选择性单胺氧化酶B活性起作用或被牵涉的疾病的药物的用途。
  • [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
    申请人:ELAN PHARM INC
    公开号:WO2004098589A1
    公开(公告)日:2004-11-18
    Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    公开的是化合物I和II的结构式,它们是激肽酶B1受体拮抗剂,适用于治疗哺乳动物中由激肽酶B1受体介导的疾病,或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力,并且预计还将表现出延长作用的特性。
  • Substituted lactams as inhibitors of A beta protein production
    申请人:——
    公开号:US20020025955A1
    公开(公告)日:2002-02-28
    This invention relates to novel lactams of Formula (I): 1 having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.
    本发明涉及具有药物和生物影响性质的新型内酰胺化合物(I)的公式,以及它们的制药组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工,更具体地抑制A&bgr;-肽的产生,从而防止淀粉样蛋白质的神经沉积形成。更具体地,本发明涉及与&bgr;-淀粉样蛋白产生相关的神经疾病的治疗,例如阿尔茨海默病和唐氏综合症。
  • [EN] MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE<br/>[FR] DERIVES DE MALONAMIDE BLOQUANT L'ACTIVITE GAMA-SECRETASE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2005023772A1
    公开(公告)日:2005-03-17
    The invention relates to malonamide derivatives of formula (I), wherein: R1 is one of the following groups (Formulae a), b), c), d)); R2 is lower alkyl, lower alkinyl, -(CH2)n-O-lower alkyl, -(CH2)n-S-lower alkyl, -(CH2)n-CN, -(CR'R')n-CF3, -(CR'R')n-CHF2, -(CR'R')n-CH2F, -(CH2)n-C(O)O-lower alkyl, -(CH2)n-halogen, or is -(CH2)n-cycloalkyl, optionally substituted by one or more substituents, selected from the group consisting of phenyl, halogen or CF3; R',R' are independently from n and from each other hydrogen, lower alkyl, lower alkoxy, halogen or hydroxy; R3, R4 are independently from each other hydrogen, lower alkyl, lower alkoxy, phenyl or halogen; R5 is hydrogen, lower alkyl, -(CH2)n-CF3 or -(CH2)n-cycloalkyl; R6 is hydrogen or halogen; R7 is hydrogen or lower alkyl; R8 is hydrogen, lower alkyl, lower alkinyl, -(CH2)n-CF3,-(CH2)n-cycloalkyl or -(CH2)n-phenyl, optionally substituted by halogen; R9 is hydrogen, lower alkyl, -C(O)H, -C(O)-lower alkyl, -C(O)-CF3,-C(O)-CH2F,-C(O)-CHF2,-C(O)-cycloalkyl,-C(O)-(CH2)n-O-lower alkyl,-C(O)O-(CH2)n-cycloalkyl, -C(O)-phenyl, optionally substituted by one or more substituents selected from the group consisting of halogen or -C(O)O-lower alkyl, or is -S(O)2-lower alkyl, -S(O)2-CF3,-(CH2)n-cycloalkyl or is -(CH2)n-phenyl, optionally substituted by halogen; n is 0, 1, 2, 3 or 4; and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixture thereof. These compounds may be used for the treatment of Alzheimer's disease.
    本发明涉及式(I)的马隆酰胺衍生物,其中:R1是以下组之一(式a,b,c,d)之一;R2是较低的烷基,较低的烯烃基,-(CH2)n-O-较低的烷基,-(CH2)n-S-较低的烷基,-(CH2)n-CN,-(CR'R')n-CF3,-(CR'R')n-CHF2,-(CR'R')n-CH2F,-(CH2)n-C(O)O-较低的烷基,-(CH2)n-卤素,或者是-(CH2)n-环烷基,选自苯基,卤素或CF3的一种或多种取代基;R',R'分别独立于n和彼此,是氢,较低的烷基,较低的烷氧基,卤素或羟基;R3,R4独立于彼此,是氢,较低的烷基,较低的烷氧基,苯基或卤素;R5是氢,较低的烷基,-(CH2)n-CF3或-(CH2)n-环烷基;R6是氢或卤素;R7是氢或较低的烷基;R8是氢,较低的烷基,较低的烯烃基,-(CH2)n-CF3,-(CH2)n-环烷基或-(CH2)n-苯基,选自卤素的一种或多种取代基;R9是氢,较低的烷基,-C(O)H,-C(O)-较低的烷基,-C(O)-CF3,-C(O)-CH2F,-C(O)-CHF2,-C(O)-环烷基,-C(O)-(CH2)n-O-较低的烷基,-C(O)O-(CH2)n-环烷基,-C(O)-苯基,选自卤素或-C(O)O-较低的烷基的一种或多种取代基,或者是-S(O)2-较低的烷基,-S(O)2-CF3,-(CH2)n-环烷基或是-(CH2)n-苯基,选自卤素的一种或多种取代基;n为0,1,2,3或4;以及药学上适用的酸盐,光学纯对映体,混合物或二对映异构体的制备方法。这些化合物可用于治疗阿尔茨海默病。
查看更多

同类化合物

艾才派硕 甲基7-氮杂双环[4.1.0]庚-3-烯-7-羧酸酯 甲基2,5-二甲基-1H-氮杂卓-1-羧酸酯 氯化二氢1-[3-(3,5,7-三甲基-2-羰基-2,3--1H-吖庚英-1-基)丙基]哌啶正离子 氮杂环庚烷-2-酮肟 氮杂环丁烷并[1,2-a]噻吩并[2,3-c]吡咯 氮杂环丁烷并[1,2-a][1,3]二氧杂环戊并[4,5-c]吡咯 氮杂环丁烷并[1,2-a][1,2]恶唑并[3,4-d]氮杂卓 氮杂卓-2,7-二酮 替尼拉平 戊四唑 吖庚英并[2,1-a]异喹啉-5(4H)-硫酮,3-甲基- 他利克索 乙基7-氧代-6-氮杂双环[3.2.0]庚-3-烯-6-羧酸酯 [4-(4-甲基苯氧基)苯基]磺酰氯 N-叔丁基-6-甲氧基-5H-吡啶并[2,3-c]氮杂-9-胺 N-丁基-6-甲氧基-5H-吡啶并[2,3-c]氮杂-9-胺 N-Boc-2,3,4,5-四氢氮杂卓 N,N-二乙基-6-硝基-3H-氮杂-2-胺 N,N-二乙基-6-甲氧基-5H-吡啶并[2,3-c]氮杂-9-胺 DL-氨基己内酰胺 C-(6,7,8,9-四氢-5H-[1,2,4]噻唑并[4,3-a]-氮杂革-3-基)-甲基胺 9-氮杂双环[4.2.1]壬-2,4-二烯-9-甲醛 9-氮杂双环[4.2.1]壬-2,4-二烯 9-氮杂双环[4.2.1]壬-2,4,7-三烯-9-甲醛 9-氧杂-6-氮杂三环[4.3.1.03,8]癸-2,4,7-三烯 8-甲基-7H-吡啶并[1,2-a]氮杂-6-酮 7-氧代-6,7-二氢-1H-氮杂卓-4-羧酸 7-氧代-6,7-二氢-1H-氮杂卓-4-磺酰胺 7-乙基-9-甲基-6,7,8,9-四氢-5H-吡嗪并[2,3-d]氮杂卓-2-胺 7-(4-氟苯基)-3,4,5,6-四氢-2H-氮杂卓 6-甲氧基-N-丙基-5H-吡啶并[2,3-c]氮杂-9-胺 6-氮杂双环[3.2.1]辛-3-烯-7-酮 6-氮杂双环[3.2.1]辛-2-烯-7-酮 6-氧杂-4-氮杂三环[5.2.1.04,8]癸-1(9),2,7-三烯 6-BOC-2-溴-5,6,7,8-四氢-4H-噻唑并[4,5-D]吖庚因 6,7-二氮杂三环[5.4.1.01,5]十二碳-2,4,8,10-四烯 6,7-二氢-9-羟基-6-氧代-5H-吡啶并[3,2-b]氮杂卓-8-羧酸乙酯 6,7-二氢-5H-吡啶并[2,3-b]氮杂革-8(9H)-酮 6,7,8,9-四氢-5H-嘧啶并[4,5-d]氮杂卓 6,7,8,9-四氢-5H-咪唑并[1,2-a]氮杂卓-2-甲醛 6,7,8,9-四氢-5H-咪唑[1,2-a]氮杂卓 6,7,8,9-四氢-5H-吡啶并[3,4-c]氮杂卓 6,7,8,9-四氢-5H-吡啶并[3,2-B]氮杂 6,7,8,9-四氢-5H-吡啶并[2,3-d]吖庚因 6,7,8,9-四氢-5H-[1,2,4]噻唑并[4,3-a]氮杂卓-3-硫醇 6,7,8,9-四氢-2-(苯甲基)-5H-嘧啶并[4,5-d]氮杂卓 6,11-二氮杂三环[5.4.0.04,8]十一碳-1(11),4,7,9-四烯 5H-嘧啶并[4,5-d]氮杂卓 5H-嘧啶并[4,5-b]氮杂卓